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Epithelioid hemangioendothelioma (EHE) is a rare tumor of
vascular origin. While it can be found in any tissue, it is most
often found in lung and liver and usually has an intermediate
behavior. EHEs originating from pleural tissue have been less
frequently described than those from other sites. Furthermore,
to date, all of the cited pleural EHEs were described as highly
aggressive. In the present report, we describe a rare case of
pleural EHE extending to lung and bone in a 31-year-old
woman. The histological diagnosis was confirmed by both
conventional examination and immunohistochemistry. Her
disease stabilized during the 4th course of adriamycin (45 mg/
m2, day 1-3), dacarbazine (300mg/m2, day 1-3) and ifosfamide
(2,500 mg/m2, day 1-3) with mesna, and she survived for 10
months after the diagnosis.
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INTRODUCTION
Epithelioid hemangioendothelioma (EHE) is a
rare tumor of vascular origin. Pulmonary epithe-
lioid hemangioendothelioma (PEH) was first des-
cribed in 1975 by Dail and Leibow and was origi-
nally termed "intravascular bronchioloalveolar
tumor (IVBAT)".
1
Dail confirmed the vascular
nature of the tumor and thus, in recent literature,
the term PEH has been used in lieu of IVBAT. PEH
has subsequently been recognized as the pulmo-
nary counterpart of EHE occurring in other sites.
EHE typically arises in variable locations such as
the lung, liver, bone, soft tissue, skin, gastro-
intestinal tract, brain, mediastinum, spleen, breast,
testis, thyroid, and heart.1 The tumor has a clinical
course intermediate between benign hemangioma
and angiosarcoma.1 Its etiology is still unknown.
EHEs originating from pleura have been less
frequently described than those from other sites.
The pleural EHE is more aggressive than others.2
Here we describe an uncommon case of pleural
EHE extending to the lungs and bone in a 31-
year-old woman. To our knowledge, this is the
first case of an EHE originating from pleura in
Korea.
CASE REPORT
A 31-year old woman was admitted to the
hospital for upper back and radiating, bilateral
shoulder pain of 5 months duration. She was a
non-smoker and had no history of asbestos ex-
posure. She complained of dull pain around the
5th vertebral body that was exacerbated in the
upright position and relieved when supine.
Physical examination and laboratory findings were
unremarkable. A chest computerized tomography
(CT) showed a nodular pleural thickening on the
right side of the chest including a 1.5 cm-sized
extrapleural tumorous lesion on the apicoposterior
segment, several foci of subpleural nodular lesions
on the right middle and lower lobes, and bone
metastases affecting the 5th and 12th thoracic
vertebral bodies (Fig. 1A). A bone scan showed a
focally increased uptake at the level of the 5th
thoracic spine, suggesting bone metastasis, and a
linear
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uptake at the 7th left anterior rib that could not
be ruled out as a possible bone metastasis (Fig. 2).
A thoracoscopic wedge resection of the right lower
lobe of the lung was performed. Grossly, the
specimen consisted of a wedge of resected lung
tissue measuring 5.0 × 3.0 × 2.5 cm with multiple
scattered and variably sized subpleural whitish-tan
plaques, at the largest diameter measuring 1.2 × 1.0
× 0.2 cm (Fig. 3). Histologically, the tumor showed
pleura-based intraparenchymal growth (Fig. 4A).
Microscopically, a hyalinized stroma surrounded
the tumor cells. The epithelioid cells contained
slightly pleiomorphic, rounded nuclei and scanty
cytoplasm with prominent intracytoplasmic
vacuoles. Few mitotic figures were observed.
Hemorrhagic necrosis was evident and surgical
margins were clear (Fig. 4B). Immunohistologi-
cally, the tumor cells were negative for cytokeratin,
calretinin, desmin, and S-100 protein (Fig. 5A).
However, the tumor cells showed diffuse strong
positivity for -SMA and vimentin, diffuse weakα
positivity for factor VIII and CD31 and focally
weak positivity for CD34 (Fig. 5B). As a result of
examination and laboratory findings, the patient
was diagnosed with pleural epithelioid hemangio-
endothelioma with peripheral lung parenchymal
invasion and multiple bone metastases to the
Fig. 1. On chest CT scan, the largest diameter of the ex-
trapleural tumorous lesion on the apicoposterior segment
is (A) 15 mm at initial diagnosis, (B) 30.7 mm after the 3rd
adriamycin (45 mg/m
2
, day 1, every 3 wks), and (C) 30.8
mm after the 2nd MAID regimen, administered every 4
wks as an injection of adriamycin (45 mg/m
2
, day 1 - 3),
dacarbazine (300 mg/m
2
, day 1 - 3) and ifosfamide (2,500
mg/m2, day 1 - 3) with mesna.
Fig. 2. A bone scan at diagnosis shows a focally increased
uptake (A) at the level of the 5th thoracic spine suggesting
bone metastasis and (B) a linear uptake at the 7th left
anterior rib that could not be ruled out as a potential
metastasis.
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spine. Palliative radiotherapy on the spine and
chemotherapy with adriamycin (45 mg/m
2
, day 1,
every 3 weeks) were started as soon as the dia-
gnosis was confirmed. When the progression of the
disease was confirmed on the chest CT after the
3rd round of adriamycin chemotherapy (Fig. 1B),
the regimen was switched to Mesna-Doxorubicin-
Ifosfamide-Dacarbazine (MAID) to be administered
every 4 weeks as an injection of adriamycin (45
mg/m2, day 1 - 3), dacarbazine (300 mg/m2, day 1
- 3) and ifosfamide (2,500 mg/m
2
, day 1 - 3) with
mesna. After the 2nd course of the MAID regimen,
the chest CT showed stable disease, and patient's
symptoms improved (Fig. 1C). She continued to
receive MAID chemotherapy and survived for 10
months after her diagnosis.
Fig. 3. Photograph of a specimen of thoracoscopic wedge
resection of the right lower lobe shows multiple scattered
and variably sized subpleural whitish-tan plaques.
Fig. 4. Histological photographs of a lung specimen show
(A) pleura-based intraparenchymal tumor growth (H & E
× 40) and (B) tumor cells surrounded by a hyalinized
stroma with intracytoplasimic vacuolization (H & E × 400).
Fig. 5. (A) Immunohistostaining shows diffuse negative
reactivity with cytokeratin (× 200). (B) Immunohisto-
staining shows diffuse positive reactivity with factor VIII
(× 200).
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DISCUSSION
The pleura is one of many anatomical sites of
origin for EHE. EHE originating from the pleura
is an extremely rare. To date, only 13 cases of
pleural EHE have been reported in the English
literature (Table 1).2-6
In many respects, pleural EHE differs from its
pulmonary counterpart (PEH). According to the
literature, pleural EHE affects symptomatic, older
adult males, while PEH usually affects asympto-
matic, young to middle-aged females.2-9 All
reported cases of diffuse pleural EHE were highly
malignant and widely metastatic regardless of the
fact that they took the form of an EHE tumor.2,3
Whereas PEH usually progresses slowly with
intermediate behavior, pleural EHE has an aggres-
sive clinical course and a poor prognosis.2-8
The poor prognostic factors of PEH include the
presence of respiratory symptoms or pleural effu-
sion on chest radiography at presentation, ex-
tensive intravascular, endobronchial, or interstitial
tumor spread, hepatic metastases, peripheral
lymphadenopathy and the presence of spindle
cells in the tumor.9 Variable chemotherapeutic
agents and radiotherapy regimens have been used
in affected patients but showed no demonstrable
therapeutic benefit. As the treatment of choice for
PEH, a surgical excision of the nodules seems to
be appropriate, although in asymptomatic patients
no therapy can be considered.8 However, in pleural
EHE, a complete surgical resection is usually
impossible. An effective treatment has not yet been
established, although Pinet et al. reported a case
of an aggressive form of pleural EHE with com-
plete remission after treatment with carboplatine
plus etoposide.4
Differentiation of pleural EHE from PEH is im-
portant because prognosis and treatment depend
on the tumor's location. A differential diagnosis
can be made by a gross or radiologic examination
on the presence or absence of a discrete nodular
mass formation in subpleural lung parenchyma
and a histological examination on an intravascular,
intraalveolar, and intrabronchial growth pattern.7
In addition, the differential diagnosis of pleural
EHE from a diffuse pleural carcinomatosis or
mesothelioma should be given careful considera-
tion due to their similar radiologic appearance. The
diagnosis of EHE is suspected based on histologi-
cal features and confirmed by immunohistoche-
mistry. Positive staining with an anti-vimentin
antibody and anti-factor VIII, BNH9, or anti-CD 31
antibodies confirms the diagnosis.10 Anti-factor
VIII and BNH 9 stain can highly distinguish
endothelial cells from others. The negativity of
anti-cytokeratin staining excludes tumors of an
epithelial origin. This is imperative for pleural
primitive tumors in order to exclude mesothelioma
or carcinoma.10
Table 1. Case Reports of Pleural Epithelioid Hemangioendotheliomas Cited in the English Literature
Authors
(No. patient)
Age/Sex Symptom Chest radiograph
Other involvement
sites
Treatment
Survival
(months)
Yousem, et al.3
(n = 1)
34/M Dyspnea Bilateral pleural
effusion
None None 3
Lin, et al.2
(n = 6)
36-58/M NA Pleural effusion (n = 5),
Pleural/pericardial
effusion (n = 1)
NA NA NA
Pinet, et al.4
(n = 1)
50/F None Right pleural effusion None Carboplatin/
etoposide
18-(CR)
Crotty, et al.
5
(n = 4)
55-71/M Chest pain
dyspnea
cough fever
Right pleural effusion Lung mediastinum
liver retroperitoneal
LN
NA 1-19
(10)
Al-Shraim, et al.6
(n = 1)
51/M Cough
dyspnea
Left pleural
effusion
Skin INF-α NA
M, male; F, female; NA, not available; LN, lymph node; CR, complete remission.
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In this report we describe a patient who was
diagnosed with pleural EHE confirmed by im-
munohistochemistry in the differential diagnosis of
a unilateral pleural effusion. The patient sustained
stable disease long-term and her symptoms im-
proved after systemic chemotherapy with adria-
mycin, dacarbazine, and ifosfamide with mesna.
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